免責事項: 本サイトは、FDA、ClinicalTrials.gov、PubMed、SEC EDGAR などの公式公開データを一般参考用に集約するものであり、医学的助言、診断、治療推奨、投資助言を構成しません。

臨床試験

An Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Vulvovaginal Candidiasis Compared With an Untreated Control Group

NCT: NCT07405853 · ACTIVE_NOT_RECRUITING

NCT識別子NCT07405853
ステータスACTIVE_NOT_RECRUITING
開始日2026-03-03
SponsorGedea Biotech AB (INDUSTRY)
First posted
Last updated

概要

The goal of this clinical trial is to learn if pHyph works to reduce signs and symptoms of vulvovaginal candidiasis (thrush). It will also learn about the safety of pHyph. The main questions it aims to answer are: * Does pHyph reduce the signs and symptoms of vulvovaginal candidiasis after an initial 6 day daily treatment? * Does an additional 6 day treatment course after the initial one further reduce signs and symptoms of vulvovaginal candidiasis? * What medical problems do participants have when applying pHyph? Researchers will compare pHyph to no treatment Day 0 to Day 7 to see if pHyph reduces signs and symptoms of vulvovaginal candidiasis. For patients that received initial treatment, researchers will also compare the treatment outcome Day 7 to the treatment outcome after an additional treatment course of pHyph, Day 14. Participants will: * Apply pHyph every day for 6 days or receive no treatment and visit the clinic 7 days after the initial screening visit. Patients that received treatment will continue with pHyph every day for 6 days and patients that did not receive any treatment will receive standard of care for vulvovaginal candidiasis and leave the study. * Patients that receive pHyph will visit the clinic Day 0 (screening), Day 7, and Day 14, and have a telephone call Day 25. Patients that do not receive pHyph will visit the clinic Day 0 (screening) and Day 7. * Keep a diary of their symptoms and confirm that they have applied pHyph.

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。

↑